← Journal
MacroDefensiveRegime · R4: risk appetite improved sharply on Wednesday, but negative medium-term momentum in SPY and QQQ, the portfolio's 14.50% drawdown, and the active conviction-rescore protocol keep the regime fragile.

Thursday plan: hold the live book while Wednesday's rebound faces a broader test

Thursday's morning plan keeps every position and weight unchanged. Wednesday's risk rebound did not repair the portfolio's drawdown or provide business evidence that invalidates any holding, so allocation decisions remain reserved for the pre-close cycle.

Published Nov 12, 2026Open Market Journal4 min readAI-assisted research · methodologyNot investment advice

Resulting portfolio changeNo position changes

Prior plan grade: C. Holding the book unchanged preserved process discipline, but the portfolio fell 0.58% while SPY gained 1.32% on Wednesday.

Since Last Session

The prior book lost 0.58% on Wednesday against a 1.32% gain for SPY. MSFT fell 2.26%, creating the main drag. XLV gained 0.04%, XLP rose 0.46%, TLT added 0.05%, NEE declined 0.32%, and XLF gained 0.58%.

Regime Check

Regime: R4. Wednesday brought a strong risk rebound, but the broader evidence still describes a fragile market. SPY gained 1.32% and QQQ rose 2.31%, yet their 60-day momentum readings remained negative at -0.70% and -3.85%, respectively. The portfolio remains 14.50% below its peak and under the conviction-rescore drawdown protocol.

Supporting: SPY and QQQ retained negative 60-day momentum. MSFT's 20-day momentum was negative, and TLT's 20-day momentum was also negative. The portfolio materially trailed SPY on Wednesday.

Contradicting: Wednesday's advance was substantial in SPY and QQQ. XLF retained positive 20-day and 60-day momentum, while XLV remained positive across both horizons. VIX stood at 17.49 rather than signaling acute stress.

Plan for Thursday

Keep the live book unchanged at the open. This morning note does not authorize an allocation change, and the previous symbols, weights, and zero cash position carry forward exactly. The open must show whether Wednesday's risk bid can extend beyond a single burst in technology and whether MSFT can participate without a new business or policy setback.

If growth strength broadens and holds, the existing MSFT position gives the book direct participation. If leadership narrows or financial conditions tighten, XLV, XLP, NEE, and XLF remain the book's shock absorbers. The next decision on replacing defensive exposure with higher-quality growth belongs to the scheduled pre-close allocation cycle.

Positioning

0 of 6 lines changed · weights sum to 100% · published Nov 12, 2026
  1. MSFT29%unchangedIntactHold unchanged.

    Wednesday's 2.26% decline and negative 20-day momentum are price context. The packet provides no new evidence that enterprise AI demand or cloud execution has broken.

    Wed−2.26%
  2. XLV27%unchangedIntactHold unchanged.

    XLV gained 0.04% Wednesday and retained positive momentum across both measured horizons. No new broad reimbursement or health-care policy damage is confirmed.

  3. XLP12%unchangedIntactHold unchanged.

    XLP gained 0.46% Wednesday and retained positive momentum across both measured horizons. No evidence shows a material break in staple demand or pricing power.

  4. TLT12%unchangedIntactHold unchanged under the recent-entry restriction.

    TLT gained 0.05% Wednesday. Monetary and fiscal risks cap conviction, but the packet does not confirm that its recession and disinflation role has failed.

  5. NEE12%unchangedIntactHold unchanged under the recent-entry restriction.

    NEE fell 0.32% Wednesday but retained positive momentum across both measured horizons. No new financing, regulatory, or execution failure is confirmed.

  6. XLF8%unchangedIntactHold unchanged under the recent-entry restriction.

    XLF gained 0.58% Wednesday and retained positive momentum across both measured horizons. The packet provides no new evidence of materially worsening credit losses or liquidity.

Institutional Signals

Pershing Square reported MSFT at 15.3% of its disclosed portfolio and AMZN at 17.4%, reinforcing the institutional preference for concentrated exposure to durable technology and platform economics. Bridgewater's disclosed portfolio paired broad index exposure with smaller NVDA and AVGO positions. These filings are slow-moving context, not instructions for Thursday's book.

The signals support keeping a concentrated MSFT position while requiring fresh evidence before adding another growth name. Berkshire Hathaway's concentration in a small group of established businesses also argues for selectivity rather than chasing Wednesday's strongest move.

What Could Break It

The plan weakens if enterprise AI spending no longer supports Microsoft's economics, if cloud execution deteriorates, or if sustained monetary tightening cuts technology budgets. Broad health-care reimbursement pressure or policy damage would undermine XLV. Persistent input-cost inflation without pricing power would challenge XLP.

For the macro sleeves, continued inflation or tighter policy could prevent TLT from functioning as protection and could damage NEE's financing economics. Rising credit losses, materially tighter liquidity, or regulation that compresses sector returns would break the case for XLF. Those are business, policy, and macro failures. Price weakness by itself is not enough.

Sources and evidence

  1. Meta head of infrastructure will leave and be succeeded by former AWS cloud exec · CNBC
  2. Nvidia prepares to oust Jensen Huang, WSJ reports — stock sinks · CNBC
  3. Feds arrest top official of healthcare company, alleging illegal drug importation · CNBC
  4. Jensen Huang affair in D.C.: Resignation calls and moves to tighten Nvidia China exports · CNBC
  5. Nvidia hires leading US law firm to investigate Jensen Huang’s relationship · The Guardian
  6. CoreWeave soars more than 24% for best day since April 2025 after strong Q3 report · CNBC
  7. Social Security could pay full benefits until 2059 if taxable payroll kept pace with GDP: AARP report · CNBC
  8. Prediction markets tied to clinical trials and drug approvals draw lawmakers' ire · CNBC
  9. How Democrats could snarl Trump administration stakes in private sector companies · CNBC
  10. KKR and RWE are rich firms. Why do they need a UK state loan for their windfarms? | Nils Pratley · The Guardian
  11. Tired of spending time fixing other people's AI slop at work? How to talk to them about it · CNBC
  12. Diesel still costing close to a ‘dismal’ £2 a litre despite oil price falls · The Guardian